Biocardia's cardiamp cell therapy chronic myocardial ischemia trial results show patient benefits in important outcomes

Sunnyvale, calif., may 01, 2024 (globe newswire) -- biocardia, inc. (nasdaq: bcda), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the cardiamp® cell therapy in chronic myocardial ischemia trial.
BCDA Ratings Summary
BCDA Quant Ranking